Table 1. Clinical characteristics of prostate cancer patients.
| Characteristic | n (%) or median (IQR) |
|---|---|
| All patients | 88 |
| Age, years | 72 (66–77) |
| PSA, ng ml–1 | 7.8 (3.8–23.7)a |
| Clinical T stage | |
| T1 | 24 (27) |
| T2 | 33 (38) |
| T3 | 19 (22) |
| T4 | 3 (3) |
| Tx | 9 (10) |
| Clinical M stage | |
| M0 | 36 (41) |
| M1 | 18 (20) |
| Mx | 34 (39) |
| Clinical N stage | |
| N0 | 38 (43) |
| N1 | 0 (0) |
| Nx | 50 (57) |
| Gleason score | |
| ⩽6 | 32 (36) |
| 7 | 26 (30) |
| 8 | 12 (14) |
| 9 | 5 (6) |
| 10 | 3 (3) |
| Unknown | 10 (11) |
| Treatment status | |
| Before diagnosis | 2 (2) |
| Untreated | 37 (42) |
| Treated | 49 (56) |
| LHRH only | 15 (31)b |
| Antiandrogens alone | 0 (0) |
| Radiotherapy alone | 5 (10) |
| Chemotherapy alone | 1 (2) |
| LHRH + antiandrogens | 10 (20) |
| LHRH + radiotherapy | 12 (24) |
| Radiotherapy + antiandrogens | 1 (2) |
| Radiotherapy + chemotherapy | 1 (2) |
| LHRH + radiotherapy + antiandrogens | 3 (6) |
| LHRH + radiotherapy + chemotherapy | 1 (2) |
Abbreviations: LHRH=luteinising hormone-releasing hormone; PSA=prostate-specific antigen; IQR=interquartile range.
a
N=85.
b
Percentage of treated group (n=49); rounded averages add up to <100%.